GSK (NYSE:GSK) Shares Up 4% - What's Next?

Key Points

• GSK shares rose by 4% on Tuesday, reaching a last trading price of $42.76, despite a significant decline in trading volume compared to average levels.
• Wall Street analysts have mixed views on GSK, with **one upgrade to "strong-buy"** but an average consensus rating of "Reduce" and a target price of $37.38 based on evaluations from six analysts.
• GSK recently reported **earnings per share of $1.23**, surpassing expectations and showing a 1.3% year-over-year revenue increase, while **dividend payments** have been set at $0.4206 per share.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) shares shot up 4% on Tuesday . The company traded as high as $42.46 and last traded at $42.76. 988,171 shares changed hands during trading, a decline of 80% from the average session volume of 4,975,473 shares. The stock had previously closed at $41.10.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Berenberg Bank restated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, GSK has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Trading Up 4.0%

The company's 50-day moving average is $39.27 and its 200-day moving average is $38.57. The firm has a market cap of $86.96 billion, a price-to-earnings ratio of 19.79, a P/E/G ratio of 1.99 and a beta of 0.53. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a $0.4206 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 3.9%. GSK's dividend payout ratio is 77.78%.

Institutional Trading of GSK

A number of institutional investors and hedge funds have recently modified their holdings of GSK. Brighton Jones LLC acquired a new position in shares of GSK in the 4th quarter valued at approximately $528,000. Wealth Enhancement Advisory Services LLC boosted its position in GSK by 8.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 174,688 shares of the pharmaceutical company's stock worth $5,908,000 after acquiring an additional 13,039 shares during the last quarter. GAMMA Investing LLC boosted its position in GSK by 7,950.3% during the 1st quarter. GAMMA Investing LLC now owns 172,277 shares of the pharmaceutical company's stock worth $66,740,000 after acquiring an additional 170,137 shares during the last quarter. Rothschild Investment LLC boosted its position in GSK by 3.3% during the 1st quarter. Rothschild Investment LLC now owns 12,272 shares of the pharmaceutical company's stock worth $475,000 after acquiring an additional 396 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in GSK by 2.1% during the 1st quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company's stock worth $713,000 after acquiring an additional 386 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.